Alzheimer's drug lecanemab approved in the US
Professor Jonathan Schott on the exciting developments of Alzheimer's drugs lecanemab and donanemab
How is Alzheimer's Research UK making a breakthrough possible
A clinical & scientific perspective on lecanemab – UK DRI Roundtable
Lecanemab for Alzheimer’s Disease: A New Hope to Slow Memory Loss
A Closer Look at Lecanemab, Donanemab and Amyloid
Hope and anxiety surround new Alzheimer’s drug lecanemab
Blood test may revolutionise treatment of Alzheimers disease | BBC News
A new era for dementia research - Susan Kohlhaas, ED of Research & Partnerships
More developments being made in Alzheimer's research
Lecanemab for Treatment of Early Alzheimer’s Disease: Overview & Clinician Perspectives
Managing Challenges in Diagnosis, Alzheimer's Research UK Clinical Conference 2022
Alzheimer's Research UK Conference Roundup 2022
New hope as Alzheimer’s drug slows memory decline in phase 3 trial
Exploring the New Alzheimer's Research UK ECR Programme
Alzheimer's drug lecanemab: "It's a major breakthrough"
Dr Fiona Calvert and Molly Massetti - Alzheimer’s Research UK’s call for Early Career Researchers
Alzheimer's Drug 'Lecanemab' Hailed As Momentous Breakthrough
Alzheimer’s breakthrough as new drug slows memory decline | 5 News
FDA approvals new Alzheimer's drug.
